CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has entered into a $35 million senior secured ...
Agreement expands Meitheal’s growing portfolio of specialty biopharmaceuticals More than 37 million people have diabetes in the United States 1 Agreement covers three biosimilars of the top selling ...
CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago focused on the development and commercialization of generic, ...
Meitheal Pharmaceuticals recently launched two new generics. The company released alprostadil injection 500 mcg/ml single-dose vials to the U.S. market, where only an ampoule form is offered. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback